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item EORTC QLQ-C30, its corresponding 13-item lung cancer 
supplement, and the EuroQol disease-generic questionnaire. 
Indirect costs of productivity loss were evaluated using the short 
form health and labor questionnaire, which includes work 
absences, reduced efficiency at work, and substitution for 
unpaid work. Time to deterioration (TTD) in HRQOL was 
calculated from time to randomization to first appearance of 
clinically significant change. TTD was analyzed using Cox 
proportional hazard models. The Embase and MEDLINE databases 
were systematically reviewed to obtain English language articles 
investigating patient-reported HRQOL after SABR for ES-NSCLC 
up to August 1, 2015. Review articles, meta-analyses and 
decision analyses were excluded. Relevant data regarding 
patient characteristics and study outcomes were abstracted and 
analyzed. 
Results:  In the ROSEL study, only TTD of global health status 
was significantly worse on univariable modeling for surgical 
patients compared to SABR (HR 0.19, p = 0.038). Indirect costing 
analysis revealed lower total productivity costs to society for 
SABR compared to surgery (€95 versus and €3,513, p = 0.044). 
Patients reported a lower total degree of hindrance in paid and 
unpaid work for SABR compared to surgery (mean hindrance 
scores for SABR: 1.9, for surgery: 6.0, p = 0.010). In the 
systematic review, nine out of 204 potential studies met all 
inclusion criteria and were analyzed. All studies were 
prospective in design. Overall SABR appeared to be well-
tolerated, in a mostly medically inoperable patient population. 
Clinically and statistically significant deteriorations in fatigue 
and dyspnea were individually reported in two studies. An 
isolated report found clinically and statistically significant 
improvements in emotional functioning over time. Deterioration 
in dyspnea and physical functioning were noted in other studies, 
but were neither statistically nor clinically significant. 
Conclusions:  SABR is an overall well-tolerated modality in 
patients with ES-NSCLC who either declined surgery or were 
unfit. Exploratory results in operable ES-NSCLC suggest that SABR 
may be better tolerated than surgery and incur indirect costing 
savings. Future clinical trials comparing SABR and surgery would 
benefit from the inclusion of HRQOL metrics in study design. 
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Purpose: In patients undergoing surgery for Stage I NSCLC, the 
delivery of neoadjuvant SABR has been proposed as a method of 
improving oncologic outcomes. A Phase II trial was launched to 
evaluate oncologic outcomes, pCR rates, and toxicity after SABR 
followed by surgical resection. The protocol mandated an 
interim safety analysis after completion of combined treatment 
in the first 10 patients. 
Methods and Materials: Operable patients with biopsy-proven 
T1T2N0 NSCLC were eligible. SABR was delivered using a risk-
adapted fractionation (54 Gy/3 fractions, 55/5 fractions or 60/8 
fractions, all with biologically effective dose > 100 Gy10), 
prescribed to the ~80% isodose line covering the planning target 
volume. Surgical resection was planned 10 weeks later, either 
lobectomy or sublobar resection, at a high-volume tertiary 
centre completing more than 200 lung cancer resections 
annually. Patients were imaged with dynamic FDG-PET CT and 
dynamic contrast enhanced CT before SABR and again before 
surgery. Toxicity was recorded using CTCAE version 4.0. 
Results: Twelve patients were enrolled between September 2014 
and September 2015. Two did not undergo surgery after SABR 
due to patient or surgeon preference; neither patient has 
developed toxicity or recurrence. For the 10 patients completing 
both treatments, median age was 70 (range 54-76), 60% had T1 
disease, and 60% had adenocarcinoma. Median FEV1 was 73% 
predicted (range 54-87%). Median time to surgery post-SABR was 
10.1 weeks (range 9.3-15.6 weeks). Surgery consisted of 
lobectomy (n = 8) or wedge resection (n = 2). Median follow up 
post-SABR was 6.3 months. After combined treatment, the rate 
of Grade 3-4 toxicity was 10% (one patient with pneumonia, atrial 
fibrillation, and respiratory failure [post-operative re-intubation 
due to mucus plugging], all resolved). Seven patients developed 
Grade 2 toxicities. Thirty- and 90-day mortality post-surgery 
were both 0%. 
Conclusions: Toxicity rates after SABR + surgical resection 
compare very favourably with reported rates in prospective 
studies of surgical resection alone (~48% Grade 3-5 toxicity after 
lobectomy [1] and ~30% after wedge resection [2]). Mature data 
on pCR rates and oncologic outcomes from this combined 
modality strategy are awaited. 
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Purpose: SBRT is an alternative treatment to surgery for Stage I 
NSCLC. Intriguingly, NSCLC lesions post-SBRT rarely exhibit a 
complete response locally and yet yield excellent local control 
of around 95%. The degree of treatment response seems to have 
little effect on in current practice. This study investigated 
tumour response post-SBRT as a clinical outcomes predictor in 
Stage I NSCLC patients. 
Methods: Survival outcomes of 233 patients were reviewed 
retrospectively from Sunnybrook Electronic Patient Record. 
Tumour sizes were collected from radiologist’s measurements 
based on CT-Scan pre and post-SBRT within 6, 12, and 18 months 
intervals. Each patient’s maximum response within 18 months 
was calculated and grouped using RECIST 1.1 methodology: 
complete response (CR), partial response (PR), stable disease 
(SD), and progressive disease (PD). 
Results: The median age of study population was 77.5 years. 
Median follow up duration was 25 months. Local control (LC), 
overall survival (OS), and non-local control (NLC) for all patients 
at two years were: 92.5, 74.6, and 68.0% respectively. Of 
patients with available pre and post-SBRT tumour sizes (n = 188), 
11 (5.9%), 92 (48.9%), 79 (42.0%), and six (3.2%) patients were 
categorized CR, PR, SD, and PD respectively using RECIST 1.1 
methodology. LC were: CR (100%), PR (94.0%), SD (89.7%), and 
PD (66.7%) respectively after two years. OS were: CR (80.0%), PR 
(80.8%), SD (72.0%), and PD (44.4%) respectively. NLC were: CR 
(100%), PR (66.4%), SD (62.5%) and PD (16.7%) respectively. 
There is a statistically significant difference in NLC between 
groups (p = 0.0009). 
Conclusions: Stage I NSCLC patients with a lesser response post-
SBRT are at higher risk of developing non-local recurrences. 
These patients may benefit from closer follow up and adjuvant 
treatment post-SBRT. 
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Purpose: Despite improved staging and operative techniques, 
rate of incomplete resection (R1) of NSCLC has remained 
significant over the last decades. Patients with R1 resection have 
significantly worse survival compared to those with complete 
resection (R0). SBRT delivers high dose radiotherapy (RT) to 
tumours, in a short time (1-10 treatments), with high precision 
while sparing normal organs. The efficacy of SBRT in treating 
small lung tumours is documented but its use as neo-adjuvant 
therapy in LA-NSCLC is not reported yet. We hypothesized that a 
short course of pre-operative SBRT can be done safely and could 
improve rates of R0 resection of LA-NSCLC and conducted a Phase 
I trial (LINNEARRE I) to investigate the safety and feasibility of 
delivering, timely, neo-adjuvant SBRT in operable patients with 
LA-NSCLC at risk for positive resection margins. 
Methods and Materials: Twenty appropriately staged (PET-
CT/MRI and mediastinal staging) patients with biopsy proven T3-
T4, N0-1, M0 NSCLC will be enrolled. Patients would be deemed 
medically operable by the surgical team but at risk of < R0 
resection (due to invasion of mediastinal or hilar structures, 
chest wall or vertebral bodies). Primary outcome is feasibility 
i.e. the ability to complete SBRT as planned and proceed to 
surgery (Sx) within six weeks. Secondary outcomes include acute 
and late adverse events, R0/R1/R2 rates and secondary 
surrogates of feasibility. SBRT is delivered in over two weeks (in 
10 fractions). Dose is escalated from 35 Gy to 50 Gy. Five patients 
will be accrued to each dose level of 35, 40, 45 and 50 Gy. At the 
latter dose level, normal tissue (nt) BED (133 Gy) exceeds that 
delivered concurrently with chemotherapy with 63-66 Gy/30 
fractions (107-110 Gy) but is similar to that delivered by recent 
dose-escalation chemo-RT (74 Gy) studies. Clinical target volume 
(CTV) includes only the area of tumour deemed at risk of 
incomplete resection expanded by 3-5 mm into surrounding 
tissues where there is clinical suspicion of invasion.  
Results: This study opened to accrual in late 2015. Dosimetric 
feasibility was tested in virtual plans of selected eligible cases 
that were planned to receive treatment at the highest planned 
dose level (50 Gy). All cases met dosimetric constraints for 
planned target volume (PTV) and organs at risk (OAR: great 
vessels, heart, esophagus, and proximal bronchi). Examples of 
virtual plans will be illustrated. 
Conclusions: This is the first study to investigate SBRT as a neo-
adjuvant therapy in LA-NSCLC. Virtual plans suggest that is 
feasible to deliver neoadjuvant SBRT safely to tumour volumes 
at risk for positive margins. A key aims of this study is to examine 
the adaptation of workflow in a Canadian academic institution 
to achieve timely neoadjuvant SBRT delivery. If successful this 
Phase I study will lead to further evaluation of pre-operative 
SBRT in LA-NSCLC, to help achieve improved rates of complete 
resection and improved outcomes. 
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Purpose: Chest wall (CW) toxicity (rib fracture and/or pain) is a 
well-known complication after stereotactic body radiotherapy 
(SBRT) for early-stage lung cancer. The aim of this study is to 
evaluate the frequency of CW toxicity following SBRT and to 
determine the dosimetric parameters that influence the risk of 
CW toxicity. 
Methods and Materials: We reviewed medical charts and 
radiotherapy (RT) plans from patients treated for T1 or T2N0 
peripheral primary lung cancer between 2009 and 2015. 
Treatment was delivered by Cyberknife®, helical tomotherapy 
or using volumetric modulated arc therapy. CW structure 
corresponded to a 3 cm expansion of the lung excluding the lung 
volume. The median total dose delivered to the planning target 
volume was 60 Gy (range, 54- 60). SBRT was delivered in 3 
fractions for patients with a CW V30 of less than 30cc. If the CW 
V30 exceeded 30cc, 5 fractions were delivered and the SBRT plan 
was optimized on the biologically equivalent parameter of CW 
V30: CW V37 < 30 cc. We studied the association between CW 
toxicity and delivered dose using the Student T-test. 
Results: Three hundred and eighty-one lesions were treated in a 
cohort of 363 patients with a median follow up of 17 months 
(range, 1 - 62). Twenty patients (6 %) had CW toxicity: 13 
patients (4%) developed CW pain and nine patients (3%) 
developed rib fractures. For patient treated in 3 fractions, the 
mean CW V30 was 21 cc for patients with CW toxicity and 16 cc 
for patients without toxicity (p < 0.05). For patients treated in 5 
fractions (n = 55), the small number of patients with chest wall 
toxicity did not allow comparison of V37 between groups. The 
CW V37 was inferior to 30 cc for all patients. CW toxicity rates 
were similar in the 3 or 5 fractions group (6% versus 4%). The 
two-year local control was similar in the two groups (96% versus 
94%). 
Conclusions: This study confirms that CW V30 is significantly 
associated with CW toxicity. When the CW V30 is greater than 30 
cc, delivering SBRT in 5 fractions and with a CW V37 of less than 
30 cc can limit CW toxicity without compromising tumour 
control. 
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Purpose: Surgery remains the standard treatment for medically 
operable patients with early-stage non-small cell lung carcinoma 
(NSCLC). Adjuvant chemotherapy is routinely recommended 
following resection of tumours > 4 cm. For patients who decline 
surgery or are medically unfit, stereotactic body radiation 
therapy (SBRT) has emerged as an excellent alternative. The 
benefit of adjuvant chemotherapy following lung SBRT has not 
been studied. To evaluate the potential benefit of such a 
treatment, we reviewed the outcomes of T2N0 patients treated 
with SBRT. 
Methods and Materials: We reviewed patients treated with SBRT 
for primary early-stage NSCLC between 2009 and 2015. Total 
target doses were between 50 and 60 Gy, administered in 3 – 8 
fractions. All patients had a staging FDG PET/CT and histologic 
confirmation was obtained whenever possible (70 %). Mediastinal 
staging (MS) was performed if lymph node involvement was 
suspected on CT or PET/CT. Survival outcomes were estimated 
using the Kaplan-Meier method. 
Results: Among the 556 NSCLC early stage patients treated with 
SBRT, 115 patients were staged T2N0. In T2N0 patients, the mean 
lesion size was 3.4 cm (range, 3 - 4.6cm). The one-year and 
three-year overall survival were 88% and 68% for patients with 
T2 disease, compare to 95% and 80% for the T1N0 patients (p < 
0.05). The median disease-free survival was higher in the T1N0 
group (48 versus 32 months). For T2N0 patients, the one-year and 
three-year local control rates were 98% and 91% respectively. 
Twenty patients (16.5%) presented a relapse, amongst which 16 
(80%) were nodal or distant. The median survival of T2N0 patient 
post-relapse was 20 months. 
Conclusions: Lung SBRT provided high local control rates, even 
for larger tumours. Overall survival and patterns of failure are 
similar to surgery. It remains to be seen if SBRT patients will be 
fit for and accepting of adjuvant chemotherapy but these results 
raise the question if adjuvant treatment is advisable post SBRT. 
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